Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Forma Therapeutics Holdings, Inc. (FMTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
18.09-0.74 (-3.93%)
At close: 4:00PM EDT
18.09 0.00 (0.00%)
After hours: 04:02PM EDT
Advertisement

Forma Therapeutics Holdings, Inc.

500 Arsenal Street
Suite 100
Watertown, MA 02472
United States
617 679 1970
http://www.formatherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees114

Key Executives

NameTitlePayExercisedYear Born
Mr. Frank D. LeePres, CEO & Director2.42MN/A1968
Mr. Todd E. ShegogSr. VP & CFO706.85kN/A1965
Dr. Patrick F. Kelly M.D.Sr. VP & Chief Medical Officer655.29kN/A1964
Dr. John E. BishopSr. VP & Chief Technology OfficerN/AN/A1962
Dr. David N. CookSr. VP & Chief Scientific OfficerN/AN/A1958
Dr. Jeannette Potts J.D., Ph.D.Sr. VP, Gen. Counsel & Corp. Sec.N/AN/A1961
Mr. Scott N. Boyle Ph.D.VP of Bus. and Corp. Devel.N/AN/AN/A
Ms. Mary E. WadlingerSr. VP of Corp. Affairs & Chief HR OfficerN/AN/A1960
Mr. Brian LesserVP & Therapeutic Head of HematologyN/AN/AN/A
Mr. Andrew Littlehale MBATreasurerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Forma Therapeutics Holdings, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement